JPET Celsis microsomes equal better data

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Harvie, P.
Right arrow Articles by Bergeron, M. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Harvie, P.
Right arrow Articles by Bergeron, M. G.

Ribavirin potentiates the efficacy and toxicity of 2',3'- dideoxyinosine in the murine acquired immunodeficiency syndrome model

P Harvie, RF Omar, N Dusserre, N Lansac, A Desormeaux, P Gourde, M Simard, M Tremblay, D Beauchamp and MG Bergeron

Centre de Recherche en Infectiologie, Centre Hospitalier de l'Universite Laval, QC, Canada.

The efficacy and toxicity of ribavirin (25 or 125 mg/kg/day), 2',3'- dideoxyinosine (ddI) (200 mg/kg/day) and a combination of both drugs at these doses given for 6 weeks were investigated in the murine acquired immunodeficiency syndrome model. Our results showed a significant protection against splenomegaly, lymphadenopathy and hypergammaglobulinemia in mice treated with ribavirin at 25 mg/kg/day alone or in combination with ddI at 200 mg/kg/day. A good synergistic effect was observed with the drug combination, whereas ddI alone (200 mg/kg/day) did not give any protection. Ribavirin/ddI combination protected against the loss of CD8 T cells in spleen and restored the capacity of splenocytes to proliferate after activation with a mitogenic agent. Moreover, the drug combination resulted in a protection of the spleen and cervical lymph node architectures and a regression of germinal centers. Hematotoxicity appeared at a dose of 125 mg/kg of ribavirin alone and increased when used concomitantly with ddI. In conclusion, ribavirin and ddI at low doses are synergistic and effective in the murine acquired immunodeficiency disease model, but at high doses they are toxic.

Volume 279, Issue 2, pp. 1009-1017, 11/01/1996
Copyright © 1996 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
 J Clin PharmacolHome page
S. Ramanathan, A. Cheng, A. Mittan, R. Ebrahimi, and B. P. Kearney
Absence of clinically relevant pharmacokinetic interaction between ribavirin and tenofovir in healthy subjects.
J. Clin. Pharmacol., May 1, 2006; 46(5): 559 - 566.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
A. Casabianca, C. Orlandi, A. Fraternale, and M. Magnani
Development of a Real-Time PCR Assay Using SYBR Green I for Provirus Load Quantification in a Murine Model of AIDS
J. Clin. Microbiol., September 1, 2004; 42(9): 4361 - 4364.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
A. Casabianca, G. Vallanti, and M. Magnani
Competitive PCR for Quantification of BM5d Proviral DNA in Mice with AIDS
J. Clin. Microbiol., August 1, 1998; 36(8): 2371 - 2374.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1996 by the American Society for Pharmacology and Experimental Therapeutics.